What does the future hold for managed entry agreements?
This article was originally published in Scrip
Managed entry agreements (MEAs), also known as risk-sharing schemes or coverage with evidence development, have become an increasingly common tool used to achieve market access in Europe. MEAs were initially designed to enable patient access to new medicines despite uncertainty regarding their effectiveness in the real-world setting. Although the first schemes involved more complex outcome-based agreements, such outcome-based schemes have given way to simpler discounts despite a global drive for payment for value, says Datamonitor Healthcare's lead analyst on market access, Dr Tijana Ignjatovic.